Brexogen, a leading biotechnology company specializing in exosome-based therapeutics, has announced a technology transfer and licensing agreement with BMI Korea for BxC-I17e, an innovative exosome-based injectable therapeutic. This agreement marks the first major licensing deal for an exosome therapeutic in Korea, signifying a major milestone in the commercialization of exosome-based medicines..

Brexogen是一家专注于外泌体治疗的领先生物技术公司，近日宣布与韩国BMI就其创新的外泌体注射疗法BxC-I17e达成技术转让和许可协议。该协议标志着韩国首个外泌体治疗产品的重大许可交易，是外泌体药物商业化进程中的重要里程碑。

Advancing Exosome Therapeutics for New Indications

推进外泌体治疗新适应症的发展

BxC-I17e is a key asset in Brexogen's pipeline and is currently undergoing clinical trials in the United States for atopic dermatitis. Recognizing its broader therapeutic potential, BMI Korea has secured rights to expand its development into potential indications excluding immunological indications, covering both domestic and key export markets..

BxC-I17e是Brexogen公司管线中的重要资产，目前正在美国进行特应性皮炎的临床试验。BMI Korea认识到其更广泛的治疗潜力，已获得将其开发扩展到免疫学适应症之外的潜在适应症的权利，覆盖韩国国内市场和主要出口市场。

While financial terms remain confidential, Brexogen will receive:

虽然财务条款仍属保密，但Brexogen将获得：

Strategic Collaboration to Accelerate Market Entry

战略性合作以加速市场进入

BMI Korea, a pharmaceutical company with annual revenues exceeding KRW 100 billion (USD 77 million), specializes in prescription drugs, biologics, medical devices, and aesthetic products. The company operates large-scale contract manufacturing (CMO) facilities in Jeju and Osong, Chungbuk, with extensive expertise in regulatory approvals, production, and commercialization..

韩国BMI公司是一家年营收超过1000亿韩元（7700万美元）的制药企业，专注于处方药、生物制品、医疗器械和美容产品。公司在济州岛和忠北五松运营着大规模的合同制造（CMO）设施，在监管审批、生产和商业化方面拥有广泛的专业知识。

Under this partnership, BxC-I17e will be manufactured at BMI Korea's cutting-edge facilities, ensuring scalability for both clinical and commercial supply.

在此合作伙伴关系下，BxC-I17e 将在 BMI Korea 的尖端设施中生产，确保临床和商业供应的可扩展性。

'Partnering with BMI Korea is a significant step forward for Brexogen,' said a Brexogen representative. 'Their robust pharmaceutical manufacturing expertise provides a strong foundation for the commercialization of BxC-I17e, allowing us to accelerate market entry while ensuring high-quality production.'.

“与韩国BMI合作是Brexogen向前迈出的重要一步，”Brexogen代表表示。“他们强大的制药生产专业知识为BxC-I17e的商业化提供了坚实的基础，使我们能够加快市场进入速度，同时确保高质量的生产。”

A BMI Korea spokesperson added:

韩国BMI发言人补充道：

'This agreement positions BMI Korea as a leader in exosome-based therapeutics. By securing one of the most advanced pipelines in the industry, we are poised to achieve Korea's first regulatory approval for an exosome therapy and expand our biopharmaceutical portfolio.'

“该协议使BMI Korea成为外泌体治疗领域的领导者。通过确保行业内最先进的管线之一，我们准备实现韩国首个外泌体疗法的监管批准，并扩大我们的生物制药组合。”

A Breakthrough for the Exosome Therapeutics Industry

外泌体治疗行业的突破

To date, globally, there is no approved exosome-based therapeutics for commercial use. This partnership is expected to drive innovation in exosome drug development and set new industry standards.

迄今为止，全球范围内尚无获批用于商业用途的外泌体疗法。该合作有望推动外泌体药物开发的创新，并树立新的行业标准。

Founded in 2019, Brexogen is a biotechnology company pioneering Natural Biomacromolecule Cargo-Controlled Exosome Technology for therapeutics, medical devices, and aesthetic applications. The company's flagship program, BRE-AD01 for atopic dermatitis, is currently in Phase 1 clinical trials in the U.S...

成立于2019年，Brexogen是一家生物技术公司，率先开发用于治疗、医疗器械和美学应用的天然生物大分子载体控制外泌体技术。该公司的旗舰项目BRE-AD01针对特应性皮炎，目前在美国正处于第一阶段临床试验。

Brexogen has also successfully commercialized BREXTEM-S (for skin rejuvenation) and BREXTEM-H (for hair restoration), offering exosome-based solutions for clinical and hospital use. Looking ahead, Brexogen is actively preparing for its KOSDAQ listing in 2026, with Korea Investment & Securities serving as the lead underwriter..

Brexogen还成功将BREXTEM-S（用于皮肤再生）和BREXTEM-H（用于头发修复）商业化，提供基于外泌体的临床和医院使用解决方案。展望未来，Brexogen正积极筹备2026年在科斯达克（KOSDAQ）上市，韩国投资证券公司（Korea Investment & Securities）担任主承销商。

This agreement between Brexogen and BMI Korea is expected to accelerate the clinical and commercial adoption of exosome-based therapeutics, paving the way for groundbreaking advancements in regenerative medicine.

Brexogen与BMI韩国之间的这项协议预计将加速基于外泌体的治疗药物的临床和商业应用，为再生医学的突破性进展铺平道路。

About Brexogen

关于布雷索根

Brexogen is a biotechnology company specializing in exosome-based therapeutics for a range of medical and aesthetic applications. Utilizing its proprietary Natural Biomacromolecule Cargo-Controlled Exosome Platform, the company is focused on developing next-generation exosome therapies and is actively advancing clinical research to establish exosomes as a new standard in regenerative medicine..

Brexogen是一家专注于外泌体治疗技术的生物技术公司，其技术可应用于多种医疗和美学领域。公司利用其专有的天然生物大分子载荷控制外泌体平台，致力于开发下一代外泌体疗法，并积极推动临床研究，旨在将外泌体确立为再生医学的新标准。

About BMI Korea

关于BMI韩国

BMI Korea is a leading pharmaceutical manufacturing and sales company, with expertise in contract manufacturing, regulatory approvals, and global distribution. The company operates large-scale biopharmaceutical and medical device production facilities and is committed to advancing innovative therapies for unmet medical needs..

BMI韩国是一家领先的制药生产和销售公司，专注于合同制造、监管审批和全球分销。该公司运营大规模的生物制药和医疗器械生产设施，并致力于推进满足未满足医疗需求的创新疗法。

Source: prnewswire.com

来源：prnewswire.com